CannAssist International Corp. (CNSC) Proprietary Tech Is Core of CBD Products with Better Absorption
- Absorption vital component of product effectiveness
- CNSC’s proprietary CiBiDinol technology is cannabidiol made water compatible
- Xceptol products offer CBD in format more in line with body’s natural bioactivity
CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company marketing its exclusive Xceptol consumer brand. The company is the owner of Xceptor Labs, which uses proprietary technology to create Xceptol CBD products. The company complex has better absorption than currently marketed oil-based products — a key advantage when assessing products’ effectiveness.
Drug absorption, or the way a drug is absorbed into the bloodstream, is a vital component in the effectiveness of treatments for a wide variety of diseases and disorders (https://nnw.fm/uFMVx). A product that claims some of the fastest rates on the market is worth paying attention to.
Numerous factors can impact the absorption of a drug into the body, including solubility, drug formulation, administration route, and gastric emptying rate. These are all factors carefully evaluated by CannAssist, which utilizes its proprietary technology — CiBiDinol — in the formulation of its products and offering that technology to third-party providers.
Developed by CannAssist founder Mark Palumbo and available through CNSC’s Xceptor Labs, CiBiDinol technology is cannabidiol made water compatible (https://nnw.fm/de75E). CiBiDinol addresses critical issues regarding CBD molecules, including delivery, bioavailability and short shelf life, by offering predictable potency, reduced dosage requirements and a wider variety of product forms. The company’s innovative process combines CBD molecules with penetration-enhancing cyclodextrin, altering the CBD molecule’s surface and rendering it water dispersible. This technology improves absorption through the skin, mucosa and gut; it also enables administration through friendly dosage forms such as capsules, drops, creams and drinks.
CannAssist notes that the technology provides CBD in a format that is more in line with the body’s natural bioactivity. Using this unique approach and exclusive technology as the basis for its entire product line, CannAssist offers an essential component for creating CBD products with more predictable potency.
Xceptor Labs uses CiBiDinol in its CBD products, which have better absorption than currently marketed oil-based products. CannAssist launched its exclusive Xceptol product line in September 2020, which initially included its unscented pain cream formulated with CiBiDinol and ingredients with National Drug Codes registered with the FDA. The company has since added capsules and liquid drops to the product line, with plans for pet drops coming soon.
CannAssist, the owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company. Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. CNSC is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets. The company has established strategic partnerships in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://nnw.fm/CNSC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Absorption vital component of product effectiveness
- CNSC’s proprietary CiBiDinol technology is cannabidiol made water compatible
- Xceptol products offer CBD in format more in line with body’s natural bioactivity
CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company marketing its exclusive Xceptol consumer brand. The company is the owner of Xceptor Labs, which uses proprietary technology to create Xceptol CBD products. The company complex has better absorption than currently marketed oil-based products — a key advantage when assessing products’ effectiveness.
Drug absorption, or the way a drug is absorbed into the bloodstream, is a vital component in the effectiveness of treatments for a wide variety of diseases and disorders (https://nnw.fm/uFMVx). A product that claims some of the fastest rates on the market is worth paying attention to.
Numerous factors can impact the absorption of a drug into the body, including solubility, drug formulation, administration route, and gastric emptying rate. These are all factors carefully evaluated by CannAssist, which utilizes its proprietary technology — CiBiDinol — in the formulation of its products and offering that technology to third-party providers.
Developed by CannAssist founder Mark Palumbo and available through CNSC’s Xceptor Labs, CiBiDinol technology is cannabidiol made water compatible (https://nnw.fm/de75E). CiBiDinol addresses critical issues regarding CBD molecules, including delivery, bioavailability and short shelf life, by offering predictable potency, reduced dosage requirements and a wider variety of product forms. The company’s innovative process combines CBD molecules with penetration-enhancing cyclodextrin, altering the CBD molecule’s surface and rendering it water dispersible. This technology improves absorption through the skin, mucosa and gut; it also enables administration through friendly dosage forms such as capsules, drops, creams and drinks.
CannAssist notes that the technology provides CBD in a format that is more in line with the body’s natural bioactivity. Using this unique approach and exclusive technology as the basis for its entire product line, CannAssist offers an essential component for creating CBD products with more predictable potency.
Xceptor Labs uses CiBiDinol in its CBD products, which have better absorption than currently marketed oil-based products. CannAssist launched its exclusive Xceptol product line in September 2020, which initially included its unscented pain cream formulated with CiBiDinol and ingredients with National Drug Codes registered with the FDA. The company has since added capsules and liquid drops to the product line, with plans for pet drops coming soon.
CannAssist, the owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company. Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. CNSC is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets. The company has established strategic partnerships in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://nnw.fm/CNSC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
